The imaging giant is leasing warehouse space and contracting inventory management through a multi-year deal with the ...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
Sonya Stokes, M.D., an emergency room physician in the San Francisco Bay Area, braces herself for a daily deluge of patients ...
Recce Pharmaceuticals’ synthetic gel successfully treated a range of skin infections in a phase 2 trial, leading the ...
Remote blood collection device maker YourBio Health is revamping its leadership team with the goal of broadening the reach of ...
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...
While the FDA’s diversity guidance for clinical trials has been temporarily restored, the page it is housed on now carries a ...
Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate, securing itself a shot ...
After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged fraudulent claims by the drug’s original maker. | After its potential kidney ...
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...
The FDA and its Center for Devices and Radiological Health (CDRH) were among several health-focused agencies caught in sweeping layoffs over the weekend as the Trump administration seeks | It’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results